Some preclinical data suggest that inhibition of EZH2 may be effective in ovarian cancer, and mechanistically, inhibition of EZH2 histone methyltransferase activity is synthetically lethal in ARID1A mutant cancers (87, 88). The gene discussed is ARID1A; the disease is ovarian cancer.